Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Abbvie Inc chart...

About the Company

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

CEO

Richard Gonzalez

Exchange

NEW YORK STOCK EXCHANGE INC.

Website

https://www.abbvie.com/

$54B

Total Revenue

50K

Employees

$321B

Market Capitalization

56.22

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ABBV News

AbbVie: An Undervalued Giant

1d ago, source:

Gevo (GEVO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, ...

AbbVie to buy Landos Biopharma for $137 million

3d ago, source:

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

1d ago, source:

AbbVie ABBV has outperformed the market over the past 10 years by 2.45% on an annualized basis producing an average annual ...

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

3d ago, source: Zacks.com on MSN

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

AbbVie signs agreement to acquire Landos Biopharma for $212.5m

2d ago, source: Pharmaceutical Technology on MSN

AbbVie has entered into a definitive agreement for the acquisition of Landos Biopharma, in a deal totalling $212.5m.

Opinion: AbbVie-Landos Deal Signals Continued Momentum for Next-Gen I&I Drugs

Opinion ago, source: BioSpace

Big Pharma’s appetite for safe and effective oral IBD drugs with novel mechanisms of action continues to grow, with my former ...

AbbVie’s New ‘Biological Missile’ Ovarian Cancer Treatment Gets Full FDA Approval

on MSN ago, source:

The Food and Drug Administration said Friday it granted full approval to AbbVie and ImmunoGen’s cancer drug ...

AbbVie To Acquire Landos Biopharma At $20.42/share In Cash

3d ago, source:

AbbVie Inc. (ABBV) and Landos Biopharma, Inc. (LABP) announced Monday a definitive agreement under which AbbVie will acquire ...

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

3d ago, source:

AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage ...

Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc

9d ago, source:

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

AbbVie Secures Full FDA Approval for ADC Elahere in Ovarian Cancer

3d ago, source: BioSpace

AbbVie’s antibody-drug conjugate Elahere on Friday won the FDA’s full approval for the treatment of FRα-positive, ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...